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Balkan Endemic Nephropathy (BEN) is a kidney disease that
progresses slowly. Only a few studies have investigated renal
clinical markers in offspring of BEN families before the onset
of the disease. This project aimed to determine whether
kidney function and structure are altered in BEN offspring
compared with non-BEN offspring. The study population
consisted of 102 adult BEN offspring and a control group of
99 non-BEN offspring. We collected urine and blood samples,
and conducted face-to-face interviews, physical examinations
and ultrasound measurements of the kidney. Total protein,
albumin, b2-microglobulin and creatinine in urine, creatinine
and urea in serum, and creatinine clearance (CCR) were
determined. Two risk factors were assessed: first, the overall
status of being an offspring from a BEN family, and second,
the specific status of a mother and/or father with BEN. The
data were analyzed using linear regression. After adjusting
for confounders, we found that kidney length and minimal
cortex width in BEN offspring were significantly decreased.
Urine concentrations of total protein, albumin, and
b2-microglobulin were higher in BEN offspring. Regarding
parental history, the associations were statistically significant
only for the offspring of mothers who had BEN, with the
exception of minimal cortex width, which showed no
parental difference. For CCR, we did not identify a statistically
significant effect for BEN offspring status nor for parental
history. In conclusion, adult offspring of BEN families can
be characterized by shorter kidney length and an increased
excretion of albumin, total protein, and b2-microglobulin,
in particular, when the mother had BEN.
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Balkan Endemic Nephropathy (BEN) was first characterized
in the Vratza District, Bulgaria, in 1956.1 Later, similar
nephropathies were described in Yugoslavia in 19572,3 and in
Romania in 1961.4 As a result, in 1964, the disease was
recognized as a new nosological entity and was named Balkan
Endemic Nephropathy. BEN is a tubulointerstitial kidney
disease that develops with no inflammation or hypertension,
and progresses slowly over many years. The final disease stage
is characterized by renal failure and shrinkage of both kidneys
to the size of walnuts.5 The disease shows familial clustering
and develops only in certain areas in the Balkan countries –
Bulgaria, Romania, Serbia and Montenegro, Croatia, and
Bosnia and Herzegovina. The spatial distribution of BEN
shows a mosaic-like pattern, with some villages afflicted for
decades, whereas others situated in the same vicinity have
remained free of BEN.6–8 The causes of BEN are still unclear.
Usually, BEN patients are diagnosed in the late stages of
the disease. There is a shortage of studies describing how the
disease develops in its earlier stages. A recent study reported a
lower creatinine clearance (CCR) in family members of
patients with BEN, but no other differences in the frequency
of renal function disorders were found when comparing
them with members of non-BEN families.9 One prior
investigation from Nis, Serbia, reported that protein and
albumin excretion was increased in children who had a family
member with BEN.10,11 This Serbian project also showed that
offspring of BEN families excreted significantly less creatinine
and that CCR was decreased.12 Another study from
Lazarevac, Serbia, reported that BEN patients in the early
phase of the disease have significantly higher CCR and
smaller kidneys in comparison to healthy controls or to
patients with renal disease other than BEN.13 It is known that
the size of both kidneys decreases as the disease pro-
gresses.14,15 However, it is unknown when the process of
shrinkage starts and how it progresses over the years.
Other BEN studies suggest that b2-microglobulin may be
the first tubular protein excreted in increased amounts.16–20
b2-microglobulin is filtered readily through the glomerular
capillary wall and almost completely resorbed by cells in the
proximal tubules, where it is metabolized.21–23 b2-micro-
globulin is a major constituent of tubular proteinuria:
elevated urinary concentration of b2-microglobulin is a
sensitive index of proximal renal tubular function.24
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The aim of this study was to determine whether clinical
markers of BEN are altered in adult offspring of BEN patients
compared with non-BEN offspring. We hypothesized that,
controlling for confounders, in as yet unaffected adult
offspring of BEN families:
1. Kidney length and minimal cortex width are reduced.
2. CCR is lower.
3. Excretion of total protein, albumin and b2-microglobulin
is higher.
RESULTS
Of 122 eligible BEN offspring, 102 participated (83.6%), and
of 120 control subjects, 99 took part (82.5%). All cases and
controls resided in Vratza, Bistretz, or Beli Izvor, but not all
were born in these settlements (Table 1). Ages ranged from 30
to 73 years. The mean age of BEN offspring was 49 years, and
for the control group, 47 years. For gender and the three age
groups, the proportion of BEN offspring and controls did not
differ statistically. BEN offspring included more current
smokers (39.2 vs 34.4%) and ex-smokers (22.6 vs 12.1%),
and more BEN offspring had a history of hypertension (22.6
vs 5.1%). Kidney stones and pyelonephritis were more often
reported by BEN offspring – 10.8 vs 4.0 and 10.8 vs 0%,
respectively. Of the 11 participants who had a history of
pyelonephritis, eight are women and three are men. We
adjusted for pyelonephritis in linear regression analyses
(Table 3). Pyelonephritis was of no importance for kidney
length and cortex width, or CCR (Cockcroft and Gault).
However, a history of pyelonephritis was weakly associated
with total protein excretion in urine (P¼ 0.059) and with
albumin excretion (P¼ 0.029), and there was no association
with b2-microglobulin.
Diabetes mellitus was equally frequent among both
groups. A parental history of other kidney diseases (other
than BEN) was more frequent in BEN offspring.
Table 2 describes the non-adjusted mean and median, and
the 5 and 95% confidence limits of the clinical markers in
BEN and non-BEN offspring. Table 3 provides the adjusted
(geometric) mean values of the clinical markers that were
found to be significantly different in offspring of BEN and
non-BEN parents. Table 3 focuses on the differences between
no parental history, maternal history, paternal history or both
parents with a history of BEN.
The mean length of the kidneys in offspring of BEN
patients was 116.5 mm, whereas in the control offspring it
was 119.4 mm (Table 2). The minimal cortex width was
15.3 mm in BEN offspring, whereas in the control offspring,
it was 15.8 mm. After adjustment for confounders, the kidney
length showed a substantial difference between the offspring
of BEN patients and control offspring: 115.9 vs 118.8 mm,
respectively (P¼ 0.007, data not shown). With regard to
parental history of BEN, having a mother with BEN was
related to a significant reduction in kidney length (Table 3).
Regarding minimal cortex width, after adjusting for
confounders (sex, place of birth, current place of residence,
age, history of smoking, diabetes, hypertension, and
pyelonephritis), BEN offspring had a significantly smaller
width compared to the controls: 15.2 vs 15.8 mm (P¼ 0.049,
data not shown). In the case of minimal cortex width, there
was no difference owing to the parental history of BEN.
For the CCR according to Cockcroft and Gault, we did not
detect any statistically significant difference for the two risk
factors under consideration: being an offspring from a BEN
family or having a mother and/or father with BEN.
Total urine protein excretion in BEN offspring was higher
than in the control offspring with median values of 181.1 and
101.1 mg/g creatinine, respectively (Table 2). Table 3 shows
that total urine protein excretion is statistically significantly
higher among offspring whose mothers had BEN than
offspring with no affected parent. The same tendency was
found for urine albumin and b2-microglobulin excretion
(Tables 2 and 3). The fact that both parents had BEN
(indicator variable) had no further effect after maternal BEN
was taken into consideration.
We additionally investigated whether the various markers
are correlated and thus measure comparable characteristics.
Most of the markers are only weakly correlated; however,
Table 1 | Characteristics of the sample
Adult offspring of BEN
patients, n=102
Adult offspring of
control patients, n=99
n % n %
Gender
Men 51 50.0 47 47.5
Women 51 50.0 52 52.5
Age (years)
30–39 17 16.7 23 23.2
40–54 55 53.9 48 48.5
55 plus 30 29.4 28 28.3
Place of birth
BEN village 96 95.0 72 72.7
Smoking status
Current smoker 40 39.2 34 34.4
Ex-smoker 23 22.6 12 12.1
Non-smoker 39 38.2 53 53.5
Other urinary tract diseases
Kidney cancer 2 2.0 0 0
Kidney stones 11 10.8 4 4.0
Pyelonephritis 11 10.8 0 0
Hydronephrosis 1 1 0 0
Cystitis 4 3.9 5 5.1
Diabetes mellitus 8 7.8 6 6.1
Hypertension 23 22.6 5 5.1
Parental history of BEN
Mother 39 38.2 0 0
Father 26 25.5 0 0
Both 37 36.3 0 0
Parental history of other kidney diseases
Mother 10 9.8 2 2.0
Father 10 9.8 0 0
BEN, Balkan Endemic Nephropathy.
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their correlation is significant (Table 4). CCR (Cockcroft and
Gault) showed a significantly positive rank correlation with
kidney length and cortex width.
When comparing average values for BEN and non-BEN
offspring within the study, the internal validity of this study is
unaffected by using the values determined by the laboratory
where this research was conducted. However, to consider
external validity, we will compare our laboratory reference
values with analogous values of other studies.
For total protein, the 24-h laboratory reference value
for this study was 24–141 mg/24 h.25 To our knowledge,
clinical reference values for total protein per gram creatinine
have not been specified. Miljkovic et al.26 studied children
and adolescents from BEN and non-BEN families. Their
average values are comparable to ours: BEN offspring
median, 181.1 mg/g creatinine (20.5 mg/mmol creatinine);
control offspring, 101.1 mg/g creatinine (11.4 mg/mmol
creatinine).
For albumin, the laboratory reference limit is up to 15 mg/
l.27 In the literature, the reference value per gram creatinine is
20 mg/g creatinine.25 Macroalbuminuria (4300 mg/g creati-
nine) was detected in 8.8% of BEN and 6.1% of the control
offspring.
The b2-microglobulin reference value of our laboratory
goes up to 300 mg/l.28 In the literature, the upper clinical limit
for b2-microglobulin is 0.2 mg/g creatinine.
25 In our sample,
5.9% of the BEN offspring and 1% of the control offspring
had values above the laboratory reference value (300 mg/l).
For serum creatinine, the laboratory reference interval was
62–124 mmol/l for men and 44–106 mmol/l for women. In the
literature, clinical references are 74–110 mmol/l for men and
58–96 mmol/l for women.25 A serum creatinine concentration
of 4110 mmol/l in men and 496 mmol/l in women was
recorded in 1% of the BEN offspring and in 3% of the control
offspring.
DISCUSSION
The results from our study show that adult offspring of BEN
families can be characterized by smaller kidney length as well
as higher excretion of albumin, total protein and b2-
microglobulin. The CCR values did not show a statistically
significant difference between BEN offspring and the control
group.
Increased b2-microglobulin urine concentration is a
nonspecific indicator of altered tubular function. Tubular
damage is generally considered the primary pathological
stage in BEN development. The increased b2-microglobulin
excretion in clinically healthy members of families with BEN,
found in this study, indicates that tubular damage may have
an early adverse effect on kidney function in population
Table 2 | Distributions of clinical markers in BEN and non-BEN offspring
Adult offspring of BEN patients Adult offspring of control patients
Variable N
Mean or
mediana 5% value 95% value N
Mean or
mediana 5% value 95% value
Length of the kidney (mm) 102 116.5 102.6 126.5 99 119.4 109.5 131.7
Minimal cortex width (mm) 102 15.3 11.5 18.0 99 15.8 12.0 19.0
Creatinine in serum (mmol/l) 102 68.3 55.0 92.9 99 71.0 49.9 96.0
Creatinine clearance (Cockcroft and Gault)
(ml/min per 1.73m2)
100 111.2 70.5 156.5 99 103.9 72.0 168.7
Total urine protein (mg/g creatinine) 102 181.1 29.6 1839.3 99 101.1 14.9 1120.2
Urine albumin (mg/g creatinine) 102 23.9 6.05 390.3 99 16.5 1.8 343.0
b2-microglobulin (mg/g creatinine) 101 99.0 44.61 350.25 99 88.99 40.63 346.59
BEN, Balkan Endemic Nephropathy.
aFor kidney length and cortex width, we used the mean, for other markers the median, since these were not normally distributed.
Table 3 | Adjusted means and their 5–95% values of the kidney and urinary markersa
Kidney length (mm)
Minimal width of
the kidney cortex
(mm)
Creatinine
clearance
(Cockcroft and
Gault) (ml/min per
1.73 m2)
Total urine protein
(mg/g creatinine)
Urine albumin
(mg/g creatinine)
b2-microglobulin
(lg/g creatinine)
n Mean 5–95% Mean 5–95%
Geom.
mean 5–95%
Geom.
mean 5–95%
Geom.
mean 5–95%
Geom.
mean 5–95%
Parental BEN
None 99 119.2 116.0–122.3 15.8 14.8–16.7 111.1 99.1–123.2 177.1 102.6–305.7 25.1 13.7–45.8 86.9 62.3–121.1
Father 26 119.1 115.5–122.6 15.1 14.0–16.1 111.6 97.9–125.2 279.5 150.7–518.5 25.0 12.6–49.4 102.8 70.6–149.7
Mother 39 113.8* 110.7–116.8 15.2 14.4–16.1 107 96.1–119.4 354.7* 209.3–601.2 44.9* 25.1–80.5 124.1* 90.0–171.0
Both 37 116.6 113.4–119.7 15.2 14.3–16.1 119.6 107.5–131.6 193.8 112.7–333.3 35.6 19.5–64.8 100.4 72.2–139.7
BEN, Balkan Endemic Nephropathy.
Geom. mean=geometric mean.
*Pp0.05.
aAdjusted for sex, place of birth (BEN and non-BEN village), current place of residence (Vratza, Bistretz, Beli Izvor), age, history of smoking (current, ex- and non-smokers),
diabetes, hypertension, and pyelonephritis.
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groups at risk for BEN. Increased b2-microglobulin excretion
along with increased albumin excretion have also been
reported in other investigations of populations in BEN
regions.17,19
Increased protein excretion, including modest albuminur-
ia, is a marker of tubulointerstitial lesions. The increased
excretion of proteins points to possible early tubular lesions
in the population at higher risk of BEN development.
However, the early detection of increased albuminuria in
clinically healthy persons can also be a sign for glomerular
lesions. Thus, alteration of these parameters, compared to the
control group, may be a sign that in addition to tubulointer-
stitial dysfunction, early glomerular dysfunction may have
occurred in the offspring of BEN patients. We cannot rule out
this possibility, and it would be consistent with a prior report
of early glomerular lesions in BEN patients.29
Regarding CCR (Cockcroft and Gault), we did not detect
any significant differences when comparing offspring of BEN
and non-BEN parents. Mitic-Zlatkovic et al.12 reported a
reduced creatinine excretion, but Djukanovic et al.13 reported
a higher CCR in BEN patients before the disease is
manifested. Thus, there is not enough evidence to conclude
whether CCR is altered before the clinical manifestation of
BEN.
The ultrasound examinations in our study revealed
reduced kidney length and cortex width in the BEN offspring
group compared to the controls. One of the most important
diagnostic criteria of BEN is the decrease in size in both
kidneys.15 However, it is not clear when the process of
symmetrical shrinkage begins. There are two different
opinions about the time when kidney size starts to decrease:
(1) along with the development of renal failure30 and (2) in
the early stages with normal glomerular filtration rate.31 Our
findings suggest that kidney length is shorter, and cortex
width is smaller, before the development of renal failure.
Thus, we support the assumption that the process of
shrinkage may begin early in life, as reported by Djukanovic
The reported biochemical and morphological changes
suggest that preclinical renal dysfunction, both tubular
and possibly glomerular, seems to be characteristic of BEN
offspring. Surprisingly, the differences in total kidney lengths,
as well as protein, albumin and b2-microglobulin excretion,
are statistically significant in relation to a maternal history of
BEN, not a paternal one. The status of both parents having
BEN did not contribute significantly once maternal history is
taken into consideration.
We did not find that birth in a BEN village was related to
clinical markers in the offspring sample of BEN and non-
BEN patients. This, in our opinion, indicates that the village
environment during pregnancy may not be of importance.
However, for all clinical markers, we found that the maternal
history of BEN is more important than the paternal. To the
Table 4 | Spearman’s rank correlation of the clinical markers
Variable
CCR (Cockcroft and
Gault) (ml/min per
1.73 m2)
b2-microglobulin
(lg/g creatinine)
Total urine
protein (mg/g
creatinine)
Urine albumin
(mg/g
creatinine)
Width of
the kidney
cortex (mm)
Kidney
length
(mm)
Creatinine in serum (mmol/l)
Correlation coefficient 0.23 0.05 0.25 0.24 0.002 0.15
Probability 0.001 0.47 0.0003 0.0006 0.98 0.036
n 199 201 201 201 201 201
CCR (Cockcroft and Gault) (ml/min per 1.73 m2)
Correlation coefficient 0.11 0.04 0.07 0.29 0.21
Probability 0.13 0.55 0.34 o0.0001 0.003
n 199 199 199 199 199
b2-microglobulin
Correlation coefficient 0.17 0.03 0.22 0.005
Probability 0.018 0.69 0.001 0.95
n 201 201 201 201
Total urine protein
Correlation coefficient 0.43 0.12 0.18
Probability o0.0001 0.095 0.01
n 201 201 201
Urine albumin
Correlation coefficient 0.08 0.28
Probability 0.24 o0.0001
n 201 201
Kidney cortex width
Correlation coefficient 0.28
Probability o0.0001
n 201
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best of our knowledge, BEN-related genetic polymorphisms
are not based on sex chromosomes. The dominant maternal
effect may, however, be initiated during the fetal period, a
time window when the fetus is exposed to the environment,
metabolism, kidney function and immune responses of the
mother. A challenge of this finding is, however, that women
in the childbearing age are not as yet diagnosed with BEN, as
the disease typically manifests after the age of 50.
As in every study, this investigation has strengths and
limitations. We do not believe that the sample is affected by a
selection bias because 83.6% of the eligible BEN offspring and
82.5% of the control subjects participated. A strength of this
study is that the hospital registry in Vratza, established in
1963, provided documentation of BEN patients who had
repeated clinical assessments. This registry facilitated the
recruitment of well-defined groups of BEN offspring.
However, offspring of BEN patients and offspring controls
included a wide age range. From our results, we can conclude
that BEN offspring have altered kidney function and length,
but we cannot determine the age of earliest detection. It
would be advantageous to investigate a birth cohort of BEN
offspring of similar age. However, cohorts of more homo-
geneous age groups can best be achieved by transnational
collaboration among the Balkan countries. Another strength
of our study is that we were able to simultaneously determine
markers of renal function and morphology. This will facilitate
the future assessment of the clinical development of the
disease.
In conclusion, our data indicate that kidney function and
size in the offspring of BEN patients are already reduced
before manifestation of the disease. Future studies are
warranted to determine the development of clinical markers
and kidney morphology over time. Given a linear develop-
ment, this information will facilitate backward extrapolation
to determine the age of onset. The strong associations of
maternal BEN with kidney function and size in their adult
offspring is intriguing and has not been reported before. This
finding indicates that future studies are needed to determine
whether maternal conditions during pregnancy, at an age
before the mother is diagnosed with BEN, may alter the
development of the kidneys and their function in the
newborn. This, in turn, may provide a new explanation of
the family disposition found for BEN. Maternal influences
during pregnancy may either directly alter the offspring’s
kidney (direct delayed effect) or may initiate gene expression
that results in altered function (epigenetic effect).
MATERIALS AND METHODS
Population/questionnaire
In the period of October 2003 to April 2004, we recruited adult
offspring (102 study subjects) whose father or mother were included
in the Vratza hospital registry of BEN patients in 2001 and resided in
three communities (Vratza, Bistretz and Beli Izvor, Bulgaria). An
equal-sized control group of adult offspring of non-BEN parents (99
study subjects) was enrolled in the study. Study subjects of both
groups were matched according to gender and 10-year age groups.
All participants provided written consent through a procedure
approved by the Institutional Review Board (human–subject
research committee) of the National Center of Public Health
Protection, Sofia, Bulgaria.
We conducted face-to-face interviews of all participants either in
the hospital or by visiting them in their home villages. The
standardized questionnaire asked for their place of residence, type
of water supply, diet, smoking, and drinking habits, medical
symptoms, family history of BEN, other kidney diseases, and kidney
tumors, and occupational history.
Clinical physical examination
The physical examination was performed by a physician with board
certification in internal medicine and nephrology. It was aimed at
assessing the general health of the study subjects and to reveal
symptoms of BEN and/or other internal diseases, which could
influence the results of laboratory tests. The examination was to
determine the status of the pulmonary, cardiovascular, and urinary
systems; gastrointestinal tract and liver; spleen and lymph nodes;
thyroid gland; and skin and visible mucous membranes. Blood
pressure was measured according to standards set by the World
Health Organization.32
Determination of kidney size
Ultrasound investigations of both kidneys took 20–30 min. The
patient was investigated lying on both the left and right sides. After
finding a suitable image, the measurements were taken. The longest
dimension of the kidney was determined. Thickness of the kidney
parenchyma (in the thinnest or minimal part), the parenchyma
structure and the relationship of parenchyma and pyelon were
measured. Information also included the location, size, and
morphology (cysts, stones and tumors) of the kidneys. The images
were saved electronically for future reference.
Urine and blood collection
Figure 1 shows the time line of the urine and blood collections.
Urine samples of the second urination in the morning were collected
at the laboratory (Figure 1), at the beginning of the 4-h sampling
period. In this urine sample, relative density, glucose, protein,
bilirubin, urobilinogen, ketones and blood were measured by strip
tests and urine sediment was examined by microscope.
After providing the second urine sample of the morning, the
study subjects had to drink 0.5 l of mineral water. From that
moment on, they collected all their urine in polyethylene containers,
which were then refrigerated. At the end of the 4-h collection period,
the urine volume was measured and recorded, and a sample was
frozen at 201C. Total protein and albumin were measured in the
4-h urine samples.
In addition, study subjects were asked to collect their urine at the
end of the first hour. This sample and any other urine collected
during the first hour were used for the determination of b2-
microglobulin. The pH of the urine was measured by pH-indicator
paper strips (Merck, NJ, USA). If the pH was lower than 7, a portion
of the urine was alkalized by adding droplets of 1 N NaOH until a pH
equal to or higher than 7 and lower than 8 was reached. A sample
from the alkalized urine was frozen at 201C for the determination
of b2-microglobulin. The rest of the urine was returned to the 4-h
urine container. The volume of the urine sample for b2-
microglobulin testing was taken into account when the 4-h urine
volume was recorded.
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Urine creatinine was measured twice: in the 1- and 4-h urine
samples. All clinical markers measured in urine were calculated as
amount per gram creatinine.
Venous blood for the determination of serum creatinine was
taken in the middle of the 4-h urine collection period. Blood was
centrifuged, serum was separated and samples were frozen at 201C.
Clinical markers of kidney function
We determined total protein, albumin, b2-microglobulin and
creatinine in urine, creatinine and urea in serum, as well as CCR.
Total protein and albumin were analyzed in the 4-h urine samples.
The preparation of albumin was carried out using latex immuno-
turbidimetric assays (Cat. No. 31924; BioSystems S.A., Spain). The
following samples were prepped with commercially available kits:
serum and urine creatinine (Jaffe photometric method, Cat. No.
0060); total urine protein (pyrogallol red photometric method, Cat.
No. 0074) and serum urea (urease/glutamate dehydrogenase
method, Cat. No. 4077). All kits were provided by Giesse
Diagnostics, Italy. Total protein, albumin, urine creatinine, serum
creatinine and serum urea were quantified with the photometric
colorimetric optical system (Roche Cobas-Mira Plus CC chemistry
analyzer; F Hoffmann-La Roche Ltd, Switzerland). The urine
collected during the first hour of the 4-h period was analyzed for
b2-microglobulin using a chemiluminescent immunoassay (Cat. No.
LKBM1; DPC, Los Angeles, CA, USA) with the Immulite analyzer
(DPC).
Quality control
Internal laboratory controls were performed with reference materials
analyzed parallel to each series of samples. For the control of b2-
microglobulin, three-level control samples were provided by DPC,
USA (Cat. No. BMCM). Control serum (two levels), produced by F
Hoffmann-La Roche Ltd, Switzerland, was used for quality control
of creatinine and urea measurements (Precinorm U, Cat. No.
171735; Precipath U, Cat. No. 171760). Control urine (normal level)
was tested in parallel with the analyses of total protein, albumin and
creatinine in urine (Cat. No. AU2352; Randox, Crumlin, UK).
Creatinine clearance
CCR was determined from serum creatinine values by using
Cockcroft and Gault formula. Specifically, it was calculated in males
as CCR Cockcroft and Gault ((140age) (body weight in kg))/
(72 serum creatinine) expressed in (ml/min per 1.73 m2).33
Further, for women, a correction factor of 0.85 was used.
Statistical analyses
Whenever clinical markers were normally distributed, we calculated
means and their 5 and 95% confidence limits. When distributions
were not normal, we used the median or conducted log
transformations and used geometric means and their confidence
limits. To answer the primary question, whether offspring of BEN
parents had altered kidney morphology and/or function, we
grouped the parental disease status: first, the overall status of being
an offspring from a BEN family, and second, the specific status of
mother, father, or both affected. In all comparisons, the reference
group was comprised only of non-BEN offspring. In addition,
parents in either group could have had other kidney disorders.
As it has been reported10–12 that offspring from villages that were
affected by occurrences of BEN had altered clinical markers, we
statistically controlled for place of birth. Whenever an offspring was
born in Vratza, Bistretz, or Beli Izvor, place of birth was labeled
‘BEN village’; all others were ‘non-BEN village’. Other confounders
used in all explanatory models include age, gender, history of
smoking, diabetes, and hypertension. For descriptive purposes, age
was grouped into three categories, 30–39, 40–54, and 55 years and
older. In the statistical analyses, we used age as a continuous
variable. For smoking, we distinguished current smoker, ex-smoker,
and non-smoker. Other non-BEN urinary tract disorders were
classified as kidney cancer, kidney stones, pyelonephritis, hydrone-
phrosis and cystitis. A participant was categorized as having a
history of hypertension if (a) increased values for blood pressure
were detected for the first time in the last 12 months, (b) higher
blood pressures were measured at several occasions, or (c) a
physician diagnosed hypertension.
We used linear regression analyses (procedure generalized linear
model (PROC GLM) of the Statistical Analysis System, SAS),34
adjusting for confounders, to determine the effect of parental status
(BEN offspring and status of the parents). To compare the effect of a
parental history of BEN, we estimated the adjusted geometric means
of the clinical markers in groups with no BEN parent, BEN mother,
BEN father, or both parents with BEN. In addition, to compare to
what extent the various markers are associated, we estimated
Spearman’s rank correlations. All statistical analyses were performed
using SAS 8.0.34
Second morning
urine sample,
followed by the
start of the two
urine collection
periods
End of 1-h
urine collection
period
End of 4-h
urine collection
period
Blood collection
(blood:
hematology,
serum:
creatinine,urea)
0800 hours 0900 hours 1000 hours 1100 hours 1200 hours
4-h urine collection (total protein, albumin, creatinine)
1-h urine collection (2-
microglobulin, creatinine)
Figure 1 | Timeline of urine and blood collection and measurements.
728 Kidney International (2006) 69, 723–729
o r i g i n a l a r t i c l e P Dimitrov et al.: Clinical markers and Balkan Endemic Nephropathy
ACKNOWLEDGMENTS
The research was supported by NIH Research Grant No. R01
TW006192 funded by the Fogarty International Center and the
National Institute of Environmental Health Sciences, National
Institutes of Health, USA, awarded to the National Center of Public
Health Protection (formerly National Center of Hygiene, Medical
Ecology, and Nutrition), Sofia, Bulgaria.
REFERENCES
1. Tanchev Y, Evstatiev Z, Dorossiev D et al. Studies on the nephritides in the
District of Vratza. Savremenna Med 1956; 7: 14–29.
2. Danilovic V, Djurisic M, Mokranjac M et al. Porodicna oboljenia bubrega u
selu Sopic izvazvana hronicnom intoksikacijom olovom. Srpski Arh Tcelok
Lek 1957; 85: 1115–1125.
3. Danilovic V, Djurisic M, Mokranjac M et al. Chronic nephritis caused by
poisoning with lead via the digestive tract (flour). Presse Med 1957; 65:
2039–2040.
4. Fortza N, Negoescu M. Nefrita cronica azotemia endo-epidemica. Stud
Cercet Med 1961; 1: 217–221.
5. Vukelic M, Sostaric B, Belicza M. Pathomorphology of Balkan endemic
nephropathy. Food Chem Toxicol 1992; 30: 193–200.
6. Tanchev Y, Dorossiev D. The first clinical description of Balkan Endemic
Nephropathy (1956) and its validity 35 years later. In: Castenagro M,
Plestina R, Dirheimer G, Chernozemsky I, Bartasch H, (eds). Mycotoxins,
Endemic Nephropathy and Urinary Tract Tumours. International Agency for
Research on Cancer: Lyon, 1991 pp 21–28.
7. Radovanovic Z. Epidemiological characteristics of Balkan Endemic
Nephropathy in Eastern regions in Yugoslavia. In: Castenagro M,
Plestina R, Dirheimer G, Chernozemsky I, Bartasch H, (eds). Mycotoxins,
Endemic Nephropathy and Urinary Tract Tumours. International Agency for
Research on Cancer: Lyon, 1991 pp 11–20.
8. Ganev V, Petropoulos E. Balkan Endemic Nephropathy and its putative
environmental and genetic causes: a review. In: Lekkas T, Pythagorion,
Samos (eds). Sixth International Conference of Environmental Science and
Technology. vol. A. University of Aegen: Greece, 1999 pp 11–21.
9. Arsenovic A, Bukvic D, Trbojevic S et al. Detection of renal dysfunctions
in family members of patients with Balkan Endemic Nephropathy. Am J
Nephrol 2005; 25: 50–54.
10. Stefanovic V, Mitic-Zlatkovic M, Cukuranovic R, Vlahovic P. Increased
urinary protein excretion in children from families with Balkan Endemic
Nephropathy. Nephron Clin Pract 2003; 95: 116–120.
11. Stefanovic V, Cukuranovic R, Mitic-Zlatkovic M, Hall PW. Increased urinary
albumin excretion in children from families with Balkan Nephropathy.
Pediatr Nephrol 2002; 17: 913–916.
12. Mitic-Zlatkovic M, Cukuranovic R, Lecic N, Stefanovic V. Urinary creatinine
excretion in children from families with Balkan endemic Nephropathy:
evidence for genetic predisposition to the disease. Pathol Biol 2000; 48:
554–557.
13. Djukanovic L, Bukvic D, Maric I. Creatininne clearance and kidney size in
Balkan endemic nephropathy patients. Clin Nephrol 2004; 61: 384–386.
14. Stefanovic V, Polenakovic M. Balkan nephropathy. Kidney disease beyond
the Balkans? [editorial]. Am J Nephrol 1991; 11: 1–11.
15. Radovanovic Z, Sindic M, Polenakovic M et al. Endemic Nephropathy.
Zavod za udzbenike i nastavna sredstva: Belgrade, 2000, 447pp.
16. Hall P, Vasilevic M. Beta2-microglobulin excretion as an index of renal
tubular disorders with special reference to endemic Balkan Nephropathy.
J Lab Clin Med 1973; 81: 897–904.
17. Karlsson F, Lenkei R. Urinary excretion of albumin and beta 2-
microglobulin in a population from an area where Balkan Nephropathy is
endemic. Scand J Clin Lab Invest 1977; 37: 169–173.
18. Hrabar A, Aleraj B, Ceovic S et al. Beta 2-microglobulin studies in endemic
Balkan Nephropathy. Kidney Int Suppl 1991; 34: S38–S40.
19. Stefanovic V, Mitic-Zlatkovic M, Cukuranovic R et al. Beta 2-microglobulin
in patients with Balkan Nephropathy and in healthy members of their
families. Kidney Int Suppl 1991; 34: S21–S26.
20. Jevremovic I, Jankovic S, Radovanovic Z et al. Beta2-microglobulinemia in
a population exposed to Balkan Endemic Nephropathy: inferences from
repeated cross-sectional studies. Kidney Int Suppl 1991; 34: S35–S37.
21. Berggard I, Bearn A. Isolation and properties of a low molecular weight
beta2-microglobulin occuring in human biological fluids. J Biol Chem
1968; 243: 4095–4103.
22. Karlsson F, Groth T, Sege K et al. Turnover of human beta2-microglobulin,
the constant chain of HLA antigens. Eur J Clin Invest 1980; 10: 293–300.
23. Peterson P, Ervin P, Berggard I. Differentiation of glomerular tubular
and normal proteinuria: determination of urinary excretion of
beta2-microglobulin, albumin and total protein. J Clin Invest 1969; 48:
1189–1198.
24. Schadurin G, Statius van Eps L. Beta2-microglobulin: its significance in the
evaluation of renal function. Kidney Int 1987; 32: 635–641.
25. Clinical Laboratory Diagnostics. Use and Assessment of Clinical Laboratory
Results, Lothar Thomas. 1st English edn. TH-Books Verlagsgeselschaft:,
1998, 1727pp.
26. Miljkovic P, Strahinjic S, Hall P et al. Urinary protein excretion in children
from families with Balkan Nephropathy. Kidney Int Suppl 1991; 34:
S24–S31.
27. Burtis C, Ashwood E (eds). Tietz Textbook of Clinical Chemistry, 3rd edn.
WB Saunders Co.: Philadelphia, 1999, 1917pp.
28. Sims H, Miller L. Beta2-microglobulin in laboratory diagnosis. Lab Med
1984; 15: 803–805.
29. Dimitrov T. Balkan Endemic Nephropathy. Bulgarian Academy of Sciences:
Sofia, 1984, 190pp (in Bulgarian).
30. Radonic M, Radosevic Z. Clinical features of Balkan Endemic
Nephropathy. Food Chem Toxicol 1992; 30: 189–192.
31. Trnacevic S, Halilbasic A, Ferluga D et al. Renal function, protein excretion
and pathology of Balkan Endemic Nephropathy. I. Renal function.
Kidney Int Suppl 1991; 34: S49–S51.
32. WHO. World Health Organization – International Society of
Hypertension guidelines for the management of hypertension,
http://new.euromise.org/mgt/who1999/who1999.html, 1999.
33. Cockcroft D, Gault M. Prediction of creatinine clearance from serum
creatinine. Nephron 1976; 16: 31–41.
34. SAS-Institute. SAS/STAT Software. SAS Institute Inc.: Cary, NC, 2000.
Kidney International (2006) 69, 723–729 729
P Dimitrov et al.: Clinical markers and Balkan Endemic Nephropathy o r i g i n a l a r t i c l e
